Acumen Pharmaceuticals Inc Cash Flow Conversion Efficiency
Acumen Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has a cash flow conversion efficiency ratio of -0.276x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.13 Million) by net assets ($87.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Acumen Pharmaceuticals Inc (2019–2025)
Cash flow conversion efficiency of Acumen Pharmaceuticals Inc from 2019 to 2025. This chart illustrates how Acumen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ABOS stock price for real-time trading data and today's change.
Acumen Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Acumen Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Acumen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Acumen Pharmaceuticals Inc (ABOS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FUTURE GAMING GRP INTL AB
F:6L50
|
0.014x |
|
Playgram Co. Ltd
KO:009810
|
0.002x |
|
Theta Edge Bhd
KLSE:9075
|
0.228x |
|
Infoline Tec Holdings Bhd
KLSE:0253
|
-0.190x |
|
Hawthorn Resources Ltd
AU:HAW
|
-0.019x |
|
Alpine Summit Energy Partners Inc
NASDAQ:ALPS
|
0.022x |
|
Pinehill Pacific Bhd
KLSE:1902
|
-0.213x |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Acumen Pharmaceuticals Inc from 2019 to 2025. Review Acumen Pharmaceuticals Inc (ABOS) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.43 Million | $-115.54 Million | -1.640x | -245.95% |
| 2024-12-31 | $181.82 Million | $-86.22 Million | -0.474x | -193.97% |
| 2023-12-31 | $266.97 Million | $-43.06 Million | -0.161x | +13.38% |
| 2022-12-31 | $188.78 Million | $-35.15 Million | -0.186x | -133.47% |
| 2021-12-31 | $225.18 Million | $-17.96 Million | -0.080x | -119.90% |
| 2020-12-31 | $-18.59 Million | $-7.45 Million | 0.401x | -32.88% |
| 2019-12-31 | $-11.42 Million | $-6.82 Million | 0.597x | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more